Safety and efficacy of aprotinin in profoundly hypothermic circulatory arrest

Journal of Cardiac Surgery

Volumn 12, Issue 2 SUPPL. 1, 1997, Pages 207-213

  Westaby, Stephen ^a,b  

^a Oxford Heart Centre   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN; APROTININ; HEPARIN; PROSTACYCLIN; PROTEIN C; PROTEIN S; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR;

ANEURYSM SURGERY; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HEART ARREST; HEMOSTASIS; HEPARINIZATION; HUMAN; INDUCED HYPOTHERMIA; PARTIAL THROMBOPLASTIN TIME; THROMBOCYTE FUNCTION;

APROTININ; BLOOD PLATELETS; HEART ARREST, INDUCED; HEMOSTATICS; HUMANS; HYPOTHERMIA, INDUCED; SERINE PROTEINASE INHIBITORS;

EID: 0030751050     PISSN: 08860440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Westaby S, Parry A, Giannopoulos N, et al: Thoracic aortic replacement with collagen-impregnated woven Dacron grafts. J Thorac Cardiovasc Surg 1993;106(3):427-33.
2. Guilmet D, Bachet J, Goudot B, et al: Use of biological glue in acute aortic dissection. A new surgical technique. Preliminary clinical results. J Thorac Cardiovasc Surg 1979;77:516-21.
3. Fisher DF Jr, Yawn DH, Crawford ES: Preoperative disseminated intravascular coagulation associated with aortic aneurysms. A prospective study of 76 cases. Arch Surg 1983;118:1252-5.
4. Heimark RL, Kurachi K, Fujikawa K, et al: Surface activation of blood coagulation, fibrinolysis and kinin formation. Nature 1980;286: 456-60.
5. Bosclair MD, Lane DA, Phillipon H, et al: Mechanism of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993;82:3350-7.
6. Tice DA, Reed GE, Clauss RH, et al: Hemorrhage due to fibrinolysis occurring with open heart operations. J Thorac Cardiovasc Surg 1963;46:673-6.
7. Harker L: Bleeding after cardiopulmonary bypass. N Eng J Med 1986;314:1446-7.
8. Harker LA, Malpass TW, Branson HE, et al: Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass, acquired transient platelet defects associated with selective alpha granule release. Blood 1980;56:824-34.
9. Ahmad N, Bube B, Agarwal GP, et al: Comparative studies of blood coagulation in hibernating and non-hibernating frogs. Thrombos Haemostas 1979;42:959-64.
10. Reed RL II, Bracey AW, Hudson JD, et al: Hypothermia and blood coagulation. Dissociation between enzymatic activity and clotting factor levels. Circ Shock 1990;32:141-52.
11. Valeri CR, Feingold H, Cassidy G, et al: Hypothermia induced reversible platelet dysfunction. Ann Surg 1987;205:175-81.
12. Zilla P, Fasol R, Groscurth P, et al: Blood platelets in cardiopulmonary bypass operations. J Thorac Cardiovasc Surg 1989;97:379-88.
13. Holloway D, Summaria L, Sandersara J, et al: Decreased platelet number and function and increased fibrinolysis contribute to post-operative bleeding in cardiopulmonary bypass patients. Thormb Haemost 1988;59:62-7.
14. Westaby S: Aprotinin in perspective. Ann Thorac Surg 1993;55:1033-41.
15. Wenger RHL, Mikuta B, Niewiarowski SLH: Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989;97:235-59.
16. Horne MK, Chao SC: Heparin binding to resting and activated platelets. Blood 1989;74:238-43.
17. Harder MPL, Eijsman L, Wildevuur CRH: Increased anticoagulation during cardiopulmonary bypass by aprotinin. J Thorac Cardiovasc Surg 1990;100:520-7.
18. Najman D, Walenga J, Fareed JRP: Effects of aprotinin on anticoagulant monitoring; implications in cardiovascular surgery. Ann Thorac Surg 1993;55:543-53.
19. Stern DM, Kaiser E, Naworth PP: Regulation of the coagulation system by vascular endothelial cells. Haemostasis 1988;18:202-14.
20. Hunt B, Segal T, Yacoub M: Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1992;104: 211-12.
21. Mackie IJ, Bull HA: Normal haemostasis and its regulation. Blood Rev 1989;3:237-50.
22. Housholder GT: The role of protein C in congenital and acquired thrombotic disorders. J Oral Maxillofac Surg 1988;46:781-7.
23. Espana F, Estefles A, Griffin J, et al: Aprotinin is a competitive inhibitor of activated protein C. Thromb Res 1989;56:751-6.
24. Kurrek MM, Reed RL: Effect of hypothermia on enzymatic activity of thrombin and plasmin. Surg Forum 1987;38:221-3.
25. Sundt TM, Saffitz JE, Stahl DJ, et al: Renal dysfunction and intravascular coagulation after use of aprotinin in thoracic aortic operation employing hypothermic circulatory arrest. Ann Thorac Surg 1993;55:1418-24.
26. Cosgrove D, Heric B, Lytic B, et al: Aprotinin therapy for reoperative myocardial revascularization: a placebo controlled study. Ann Thorac Surg 1992;54:1031-8.
27. Westaby S, Forni A, Dunning J, et al: Aprotinin and bleeding in profoundly hypothermic perfusion. Eur J Cardiothorac Surg 1994;8:82-6.
28. Havel M, Griesmacher A, Weigel G, et al: Aprotinin decreases 6-keto-prostaglandin F12 and decreases release of thromboxane A2 in cultured human umbilical vein endothelial cells. J Thorac Cardiovasc Surg 1992;104:654-8.
29. Wang J, Lin C, Hung W, et al: In vitro effects of aprotinin on activated clotting time measured with different activators. J Thorac Cardiovasc Surg 1992;104:1135-40.
30. Goldstein DJ, DeRosa CM, Mongero LBS, et al: Safety and efficacy of aprotinin under deep hypothermia and circulatory arrest. J Thorac Cardiovasc Surg 1995;110:1615-21.
31. Regragui IA, Bryan AJ, Izzat MB et al: Aprotinin use with hypothermic circulatory arrest for aortic valve and thoracic aortic surgery: renal function and early survival. J Heart Valve Dis 1995; 4(6):674-7.
32. O'Regan DJ, Giannopoulos N, Mediratta N, et al: Topical aprotinin in cardiac operations. Ann Thorac Surg 1994;58(3):778-81.